Abstracts tagged "clinical trials"

Abstract Number: 2910 • 2019 ACR/ARP Annual Meeting
Improving the Efficiency of Clinical Trial Recruitment Using Electronic Health Record Data, Natural Language Processing, and Machine Learning
Tianrun Cai¹, Fiona Cai ², Kumar Dahal ³, Chuan Hong ⁴ and Katherine Liao ¹, ¹Brigham and Women's Hospital, Boston, ²Stuyvesant High School, New York, ³Brigham and Women's Hospital, Boston, MA, ⁴Harvard Medical School, Boston, MA
Background/Purpose: Efficiently identifying eligible patients is an important component of a successful clinical trial. Billing codes from electronic health record (EHR) data are commonly used…
Abstract Number: 222 • 2019 ACR/ARP Annual Meeting
Acupuncture for Chronic Musculoskeletal Pain: A Review of Randomized Controlled Trials
Yujuan Zhang¹ and Chenchen Wang ², ¹Floating Hospital at Tufts Medical Center, Boston, ²Tufts Medical Center, Boston
Background/Purpose: Acupuncture has been widely used for pain relief in adults. Evidence on effects of acupuncture for pediatric chronic musculoskeletal pain is scarce. We have reviewed existing…
Abstract Number: 1298 • 2019 ACR/ARP Annual Meeting
A Randomised Clinical Trial of Curcuma Longa Extract for Treating Symptoms and Effusion-Synovitis of Knee Osteoarthritis
Zhiqiang Wang ¹, Graeme Jones ², Tania Winzenberg ¹, Guoqi Cai ¹, Laura Laslett ², Dawn Aitken ¹, Ingrid Hopper ³, Robert Jones ⁴, Changhai Ding ², Jurgen Fripp ⁵ and Benny Antony², ¹Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia, ²Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ³Department of Epidemiology, Monash University, Melbourne, Victoria, Australia, ⁴Royal Hobart Hospital, Hobart, Tasmania, Australia, ⁵The University of Queensland, Brisbane, Queensland, Australia
Background/Purpose: Pharmacological therapies are limited, associated with off-target effects, are frequently contraindicated, and only modestly effective for pain in osteoarthritis (OA). Effusion and synovitis are…
Abstract Number: 390 • 2019 ACR/ARP Annual Meeting
Preliminary Response to Janus Kinase (JAK) Inhibition with Baricitinib in Refractory Juvenile Dermatomyositis
Hanna Kim¹, Samantha Dill ², Michelle O'Brien ², Minal Jain ³, Shajia Lu ⁴, Wanxia Tsai ⁴, Yinghui Shi ⁵, Laura Vian ⁴, Massimo Gadina ⁴, Michelle Millwood ², April Brundidge ², Lisa G. Rider ⁶ and Robert Colbert ¹, ¹Pediatric Clinical Trials Unit, Pediatric Translational Research Branch, NIAMS, NIH, Bethesda, MD, ²Pediatric Clinical Trials Unit (PCTU), Office of the Clinical Director, NIAMS, NIH, Bethesda, MD, ³Rehabilitation Medicine Department, Physical Therapy Section, Clinical Research Center, NIH, Bethesda, MD, ⁴Translational Immunology Section, NIAMS, NIH, Bethesda, MD, ⁵Office of Clinical Director, NIAMS, NIH, Bethesda, MD, ⁶Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Bethesda, MD
Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic autoimmune disease with a prominent interferon (IFN) signature. Treatment often requires prolonged high-dose steroids and other immunosuppressive medications.…
Abstract Number: 1303 • 2019 ACR/ARP Annual Meeting
Intra-Articular TPX-100 Significantly Delays Pathological Bone Shape Change at 6 and 12 Months in Moderate to Severe Tibiofemoral OA
Dawn McGuire¹, Michael Bowes ², Alan Brett ², Neil Segal ³, Meghan Miller ⁴, David Rosen ⁴ and Yoshinari Kumagai ⁴, ¹OrthoTrophix, Orinda, CA, ²Imorphics, Manchester, England, United Kingdom, ³University of Kansas Medical Center, Kansas City, KS, ⁴OrthoTrophix, Oakland, CA
Background/Purpose: Pathological bone shape changes in the femur precede cartilage changes in knee OA and predict disease onset and progression to joint failure (Neogi 2013;…
Abstract Number: 1715 • 2018 ACR/ARHP Annual Meeting
Safety and Efficacy of Lenabasum in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects
Robert F. Spiera¹, Laura K. Hummers², Lorinda Chung³, Tracy M. Frech⁴, Robyn T. Domsic⁵, Vivien Hsu⁶, Daniel E. Furst⁷, Jessica K. Gordon¹, Maureen D. Mayes⁸, Robert W. Simms⁹, Elizabeth Lee¹⁰, Scott Constantine¹⁰ and Barbara White¹⁰, ¹Hospital for Special Surgery, New York, NY, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ⁴Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁵Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁶Rheumatology, Robert Wood Johnson Medical School, New Brunswick, NJ, ⁷Pacific Arthritis Associates, Los Angeles; University of California, Los Angeles; University of Washington, Seattle; University of Florence, Italy, Los Angeles, CA, ⁸Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁹Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁰Corbus Pharmaceuticals, Inc., Norwood, MA
Background/Purpose: Lenabasum is a synthetic, non-immunosuppressive, selective cannabinoid receptor type 2 agonist that activates resolution of innate immune responses. Lenabasum had acceptable safety and tolerability,…
Abstract Number: 302 • 2018 ACR/ARHP Annual Meeting
Validity and Responsiveness of Inflammation and Joint Damage Scores Based on the Omeract Rheumatoid Arthritis MRI Scoring System
Ulf Sundin¹, Mikkel Østergaard², Daniel Glinatsi³, Anna-Birgitte Aga⁴, Kim Hørslev-Petersen⁵, Merete Lund Hetland⁶, Peter Junker⁷, Bo Jannik Ejbjerg⁸, Paul Bird⁹, Philip G. Conaghan¹⁰, Siri Lillegraven⁴ and Espen A. Haavardsholm⁴, ¹*Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup Copenhagen Center for Arthritis Research, Copenhagen, Denmark, ³Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark, ⁴Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵King Christian 10th Hospital for Rheumatic Diseases, University of Southern Denmark, Institute of Regional Health Research, Graasten, Denmark, ⁶Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, The DANBIO Registry, Glostrup, Denmark, ⁷Odense University Hospital, Odense, Denmark, ⁸Department of Rheumatology, Zealand University Hospital, Køge, Denmark, ⁹Medicine, University of New South Wales, Sydney, NSW, Australia, ¹⁰University of Leeds, Leeds, United Kingdom
Background/Purpose: The RAMRIS scoring system is used to quantify synovitis, tenosynovitis, bone marrow edema (BME), bone erosions and joint space narrowing (JSN) on MRI examinations…
Abstract Number: 1872 • 2018 ACR/ARHP Annual Meeting
Safety and Efficacy of Allogeneic Umbilical Cord-Derived Mesenchymal Stem Cells in Patients with Systemic Lupus Erythematosus: Results of an Open-Label Phase I Study
Diane L. Kamen¹, Paul J. Nietert², Hongjun Wang³, Tara Duke³, Colleen Cloud³, Angela Robinson³ and Gary S. Gilkeson⁴, ¹Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ²Public Health Sciences, Medical University of South Carolina, Charleston, SC, ³Medical University of South Carolina, Charleston, SC, ⁴Department of Medicine, Medical University of South Carolina, Charleston, SC
Background/Purpose: Mesenchymal stem cells (MSCs) are known to possess significant immunosuppressive and tissue protective properties, and their use in refractory systemic lupus erythematosus (SLE) is…
Abstract Number: 478 • 2018 ACR/ARHP Annual Meeting
Evidence Based Recommendations for Corticosteroid Tapering/Discontinuation in New Onset Juvenile Dermatomyositis Patients: Results from the Paediatric Rheumatology International Trials Organisation
Gabriella Giancane¹, Claudio Lavarello², Angela Pistorio², Francesco Zulian², Bo Magnusson³, Tadej Avcin², Fabrizia Corona², Valeria Gerloni², Serena Pastore², Roberto Marini², Silvana Martino², Anne Pagnier⁴, Michel Rodiere², Christine Soler², Valda Stanevicha², Rebecca ten Cate², Yosef Uziel², Jelena Vojinovic², Elena Fueri², Angelo Ravelli⁵, Alberto Martini⁶ and Nicola Ruperto⁷, ¹Clinica Pediatrica - Reumatologia, Istituto Giannina Gaslini, Genoa, Italy, ²Istituto Giannina Gaslini - Clinica Pediatrica e Reumatologia - PRINTO, Genoa, Italy, ³Karolinska University Hospital, Stockholm, Sweden, ⁴Istituto Giannina Gaslini - Clinica Pediatrica e Reumatologia - PRINTO, Genova, Italy, ⁵Clinica Pediatrica - Reumatologia, Istituto Giannina Gaslini, Genova, Italy, ⁶Universita di Genova Pediatria II, Genova, Italy, ⁷Istituto Giannina Gaslini - Clinica Pediatrica e Reumatologia, Genoa, Italy
Background/Purpose: At present no clear evidence based guidelines exist to standardize the tapering and discontinuation of corticosteroids (CS) in juvenile dermatomyositis (JDM). Aim of our…
Abstract Number: 2284 • 2018 ACR/ARHP Annual Meeting
Safety and Efficacy of Lenabasum in Refractory Skin-Predominant Dermatomyositis Subjects Treated on an Open-Label Extension of Trial JBT101-DM-001
Victoria P. Werth^1,2, David Pearson^1,2, Joyce Okawa^1,2, Rui Feng³, Josef Concha^1,2, Basil Patel^1,2, Emily Hejazi^1,2, Caitlin Cornwall⁴, Scott Constantine⁴ and Barbara White⁴, ¹University of Pennsylvania, Philadelphia, PA, ²Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, ³University of Pennsylvania, Philadelphia', PA, ⁴Corbus Pharmaceuticals, Inc., Norwood, MA
Background/Purpose: Lenabasum is a synthetic, non-immunosuppressive, selective cannabinoid receptor type 2 agonist that activates resolution of innate immune responses. Lenabasum had acceptable safety and tolerability…
Abstract Number: 662 • 2018 ACR/ARHP Annual Meeting
Radiographic Progression of Structural Joint Damage in Patients with Active Psoriatic Arthritis Treated with Ixekizumab for up to 3 Years
Désirée van der Heijde¹, Vinod Chandran², Roy Fleischmann³, Olivier Benichou⁴, Suchitrita Rathmann⁴ and Catherine Shuler⁴, ¹Leiden University Medical Centre, Leiden, Netherlands, ²Krembil Research Institute & University of Toronto, Toronto, ON, Canada, ³University of Texas Southwestern Medical Center, Dallas, TX, ⁴Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Ixekizumab (IXE), an IL-17A antagonist, was shown to be superior to placebo (PBO) in inhibiting the progression of structural joint damage in patients (pts)…
Abstract Number: 2356 • 2018 ACR/ARHP Annual Meeting
Perceptions, Incentives, and Barriers to Clinical Trial Participation: Qualitative Evaluation of Lupus Patients, Enriched for Minority Participants
Cristina Arriens¹, Fredonna Carthen², D'Angelo Grant², Paul Kamp¹, Stan Kamp¹, Katherine Thanou¹, Teresa Aberle¹, Eliza Chakravarty¹, Judith A. James³, Joan T. Merrill¹ and Motolani E. Ogunsanya⁴, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, OKLAHOMA CITY, OK, ³Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Although SLE disproportionately affects minority racial groups, they are significantly under-represented in clinical trials. This may lead to false, underpowered conclusions in race-based sub-group…
Abstract Number: 686 • 2018 ACR/ARHP Annual Meeting
Five-Year Efficacy and Safety of Apremilast Treatment in Subjects with Psa: A Pooled Analysis of the 3 Phase III Studies
Arthur Kavanaugh¹, Dafna D Gladman², Christopher J. Edwards³, Georg Schett⁴, Benoit Guerette⁵, Nikolay Delev⁵, Lichen Teng⁵, Maria Paris⁵ and Philip J. Mease⁶, ¹University of California, San Diego, School of Medicine, La Jolla, CA, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³University of Southampton, Southampton, United Kingdom, ⁴Friedrich-Alexander-Universität Erlangen, Nürnberg und Universitätsklinikum Erlangen, Erlangen, Germany, ⁵Celgene Corporation, Summit, NJ, ⁶Swedish Medical Center and University of Washington School of Medicine, Seattle, WA
Background/Purpose: Long-term apremilast (APR) efficacy and safety were evaluated for up to 5 yrs in adults with active PsA in the phase III PALACE 1-3…
Abstract Number: 2483 • 2018 ACR/ARHP Annual Meeting
Major Secular Trends of Patient Characteristics and Inclusion Criteria in RA Clinical Trials
Andreas Kerschbaumer¹, Bruno Bierbaumer², Josef S. Smolen³ and Daniel Aletaha⁴, ¹Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Independent, Munich, Germany, ³Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ⁴Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Rheumatoid arthritis (RA) is among the most intensively studied chronic inflammatory musculoskeletal diseases. Over the past two decades numerous new compounds have been tested…
Abstract Number: 838 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Combined Immunosuppressive Therapy with High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Disease Accompanied By Anti-MDA5-Positive Dermatomyositis -a Multicenter Prospective Study –
Hideaki Tsuji¹, Ran Nakashima¹, Yoshitaka Imura², Masato Yagita², Hajime Yoshifuji¹, Shintaro Hirata³, Takaki Nojima³, Eiji Sugiyama⁴, Kazuhiro Hatta⁵, Yoshio Taguchi⁶, Masaki Katayama⁷, Shuji Akizuki¹, Kosaku Murakami¹, Motomu Hashimoto⁸, Masao Tanaka⁸, Koichiro Ohmura¹ and Tsuneyo Mimori⁹, ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Department of Clinical Immunology and Rheumatology, The Tazuke-Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan, ³Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, ⁴Department of Clinical Immunology and Rheumatology, Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, ⁵Department of General Medicine, Tenri Hospital, Tenri, Japan, ⁶Department of Respiratory Medicine, Tenri Hospital, Tenri, Japan, ⁷Department of Rheumatology and Clinical Immunology, Osaka Red Cross Hospital, Osaka, Japan, ⁸Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁹Department of Rheumatology and Clinical Immunology, Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Background/Purpose: Interstitial lung disease (ILD) accompanied by anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis (DM) is often rapidly progressive and associated with poor life prognosis in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].